Castro-Rodriguez Jose A, Beckhaus Andrea A, Forno Erick
Division of Pediatrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania.
Pediatr Pulmonol. 2016 Aug;51(8):868-76. doi: 10.1002/ppul.23429. Epub 2016 Apr 13.
Systemic corticosteroids (SCS) are used for treat preschoolers with acute asthma or wheezing exacerbations, with conflicting results.
To evaluate the effectiveness of oral corticosteroids (OCS) compared to placebo in preschoolers presenting with acute asthma/wheezing exacerbations.
Five electronic databases were searched for all placebo-controlled, randomized clinical trials of OCS in children <6 years of age presenting with recurrent wheezing/asthma exacerbations of any severity. Primary outcomes were hospitalizations, unscheduled emergency department (ED) visits in following month, need of additional OCS courses, and length of stay (ED or hospital).
Eleven studies met inclusion criteria (n = 1,733); four were conducted on an outpatient basis, five in inpatients, and two in the ED. Significant heterogeneity was found when pooling all studies, and thus analysis was stratified by trial setting. Among the outpatient studies, children who received OCS had a higher hospitalization rate (RR: 2.15 [95%CI = 1.08-4.29], I(2) = 0%) compared to those to received placebo. Among the ED studies, children who received OCS had a lower risk of hospitalization (RR: 0.58 [0.37-0.92], I(2) = 0%). Among the inpatient studies, children who received OCS needed fewer additional OCS courses than those on placebo (RR: 0.57 [0.40-0.81], I(2) = 0%).
Treatment with OCS in the ED or hospital may be beneficial in toddlers and preschoolers with frequent asthma/wheezing exacerbations. However, more studies are needed before OCS can be broadly recommended for this age group. Future trials should be carefully designed to avoid bias and according to our findings regarding administration setting. Pediatr Pulmonol. 2016;51:868-876. © 2016 Wiley Periodicals, Inc.
全身用皮质类固醇(SCS)用于治疗患有急性哮喘或喘息加重的学龄前儿童,但其结果存在争议。
评估口服皮质类固醇(OCS)与安慰剂相比,对患有急性哮喘/喘息加重的学龄前儿童的疗效。
检索了五个电子数据库,查找所有针对6岁以下患有复发性喘息/任何严重程度哮喘加重的儿童进行的OCS安慰剂对照随机临床试验。主要结局包括住院、次月计划外急诊就诊、需要额外的OCS疗程以及住院时间(急诊或住院)。
11项研究符合纳入标准(n = 1,733);4项在门诊进行,5项在住院患者中进行,2项在急诊科进行。汇总所有研究时发现显著异质性,因此按试验设置进行分层分析。在门诊研究中,与接受安慰剂的儿童相比,接受OCS的儿童住院率更高(风险比:2.15 [95%置信区间 = 1.08 - 4.29],I² = 0%)。在急诊科研究中,接受OCS的儿童住院风险较低(风险比:0.58 [0.37 - 0.92],I² = 0%)。在住院患者研究中,接受OCS的儿童比接受安慰剂的儿童需要的额外OCS疗程更少(风险比:0.57 [0.40 - 0.81],I² = 0%)。
在急诊科或医院使用OCS治疗可能对频繁哮喘/喘息加重的幼儿和学龄前儿童有益。然而,在OCS能够被广泛推荐用于该年龄组之前,还需要更多的研究。未来的试验应精心设计以避免偏倚,并根据我们关于给药设置的研究结果进行。《儿科肺科杂志》。2016年;51:868 - 876。© 2016威利期刊公司。